{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:59:22Z","timestamp":1789595962097,"version":"build-2803163510"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2002,11]]},"DOI":"10.1007\/s11916-002-0065-y","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T03:16:44Z","timestamp":1180840604000},"page":"460-469","source":"Crossref","is-referenced-by-count":49,"title":["Botulinum toxin for the treatment of musculoskeletal pain and spasm"],"prefix":"10.1007","volume":"6","author":[{"given":"Geoffrey","family":"Sheean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"suppl 1","key":"65_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/PL00007816","volume":"248","author":"R Aoki","year":"2001","unstructured":"Aoki R: Pharmacology and immunology of botulinum toxin serotypes. J Neurol 2001, 248(suppl 1):3\u201310.","journal-title":"J Neurol"},{"key":"65_CR2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1212\/WNL.40.2.277","volume":"40","author":"J Jankovic","year":"1990","unstructured":"Jankovic J, Schwartz K: Botulinum toxin injections for cervical dystonia. Neurology 1990, 40:277\u2013280.","journal-title":"Neurology"},{"key":"65_CR3","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1055\/s-2001-18651","volume":"126","author":"A Chadlkiadaki","year":"2001","unstructured":"Chadlkiadaki A, Rohr UP, Hefter H: Early pain reduction in the treatment of spasticity after a single injection of botulinum A toxin. Deutsch Med Wochenschr 2001, 126:1361\u20131364.","journal-title":"Deutsch Med Wochenschr"},{"key":"65_CR4","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0022-510X(97)00151-2","volume":"152","author":"N Giladi","year":"1997","unstructured":"Giladi N: The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J Neurol Sci 1997, 152:132\u2013135.","journal-title":"J Neurol Sci"},{"key":"65_CR5","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11916-999-0069-y","volume":"3","author":"BM Guyer","year":"1999","unstructured":"Guyer BM: Mechanism of botulinum toxin in the relief of chronic pain. Curr Rev Pain 1999, 3:427\u2013431.","journal-title":"Curr Rev Pain"},{"key":"65_CR6","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1517\/13543784.10.8.1531","volume":"10","author":"GE Borodic","year":"2001","unstructured":"Borodic GE, Acquadro M, Johnson EA: Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin Investig Drugs 2001, 10:1531\u20131544.","journal-title":"Expert Opin Investig Drugs"},{"key":"65_CR7","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1526-4610.2000.00066.x","volume":"40","author":"S Silberstein","year":"2000","unstructured":"Silberstein S, Mathew N, Saper J, Jenkins S: Botulinum toxin type A as a migraine preventive treatment: for the Botox Migraine Clinical Research Group. Headache 2000, 40:445\u2013450.","journal-title":"Headache"},{"issue":"suppl 1","key":"65_CR8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/PL00007812","volume":"248","author":"AO Ceballos-Baumann","year":"2001","unstructured":"Ceballos-Baumann AO: Evidence-based medicine in botulinum toxin therapy for cervical dystonia. J Neurol 2001, 248 (suppl 1):14\u201320.","journal-title":"J Neurol"},{"issue":"suppl 1","key":"65_CR9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/PL00007814","volume":"248","author":"G Reichel","year":"2001","unstructured":"Reichel G: Botulinum toxin for treatment of spasticity in adults. J Neurol 2001, 248 (suppl 1):25\u201327.","journal-title":"J Neurol"},{"key":"65_CR10","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1054\/bjom.1999.0238","volume":"38","author":"B Freund","year":"2000","unstructured":"Freund B, Schwartz M, Symington JM: Botulinum toxin: new treatment for temporomandibular disorders. Br J Oral Maxillofac Surg 2000, 38:466\u2013471.","journal-title":"Br J Oral Maxillofac Surg"},{"key":"65_CR11","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1159\/000018779","volume":"16","author":"Lopez F Fernandez","year":"1999","unstructured":"Fernandez Lopez F, Conde Freire R, Rios Rios A, et al.: Botulinum toxin for the treatment of anal fissure. Dig Surg 1999, 16:515\u2013518.","journal-title":"Dig Surg"},{"key":"65_CR12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/bega.1999.0013","volume":"13","author":"WA Hoogerwerf","year":"1999","unstructured":"Hoogerwerf WA, Pasricha PJ: Botulinum toxin for spastic gastrointestinal disorders. Baillieres Best Pract Res Clin Gastroenterol 1999, 13:131\u2013143.","journal-title":"Baillieres Best Pract Res Clin Gastroenterol"},{"issue":"suppl 1","key":"65_CR13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/PL00007818","volume":"248","author":"H Gobel","year":"2001","unstructured":"Gobel H, Heinze A, Heinze-Kuhn K, Jost WH: Evidence-based medicine: botulinum toxin A in migraine and tension-type headache. J Neurol 2001, 248 (suppl 1):34\u201338.","journal-title":"J Neurol"},{"key":"65_CR14","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1212\/WNL.56.10.1290","volume":"56","author":"L Foster","year":"2001","unstructured":"Foster L, Clapp L, Erickson M, Jabbari B: Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology 2001, 56:1290\u20131293. This is the only controlled study of botulinum toxin in the treatment of low back pain. Patients receiving botulinum toxin-A obtained greater pain relief and improved function compared with the placebo group. Although only 31 patients were observed, the results are encouraging.","journal-title":"Neurology"},{"key":"65_CR15","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/ptj\/65.9.1347","volume":"65","author":"DJ Miller","year":"1985","unstructured":"Miller DJ: Comparison of electromyographic activity in the lumbar paraspinal muscles of subjects with and without chronic low back pain. Phys Ther 1985, 65:1347\u20131354.","journal-title":"Phys Ther"},{"key":"65_CR16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0304-3959(84)90093-9","volume":"20","author":"A Nouwen","year":"1984","unstructured":"Nouwen A, Bush C: The relationship between paraspinal EMG and low back pain. Pain 1984, 20:109\u2013123.","journal-title":"Pain"},{"key":"65_CR17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1300\/J094v09n01_08","volume":"9","author":"AH Wheeler","year":"2001","unstructured":"Wheeler AH, Goolkasian P: Open-label assessment of botulinum toxin A for pain treatment in a private outpatient setting. J Musculoskeletal Pain 2001, 9:67\u201382.","journal-title":"J Musculoskeletal Pain"},{"key":"65_CR18","first-page":"481","volume":"27","author":"BJ Freund","year":"2000","unstructured":"Freund BJ, Schwartz M: Treatment of whiplash associated neck pain [corrected] with botulinum toxin-A: a pilot study. J Rheumatol 2000, 27:481\u2013484.","journal-title":"J Rheumatol"},{"key":"65_CR19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0304-3959(01)00358-X","volume":"94","author":"AH Wheeler","year":"2001","unstructured":"Wheeler AH, Goolkasian P, Gretz SS: Botulinum toxin A for the treatment of chronic neck pain. Pain 2001, 94:255\u2013260. A study including 50 patients that showed no benefit of botulinum toxin type A injections.","journal-title":"Pain"},{"issue":"suppl 1","key":"65_CR20","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1053\/apmr.2002.32155","volume":"83","author":"J Borg-Stein","year":"2002","unstructured":"Borg-Stein J, Simons DG: Myofascial pain. Arch Phys Med Rehabil 2002, 83(suppl 1):S40-S47. An excellent summary of myofascial pain syndrome, with detailed discussion of the pathophysiology.","journal-title":"Arch Phys Med Rehabil"},{"key":"65_CR21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0304-3959(94)90048-5","volume":"59","author":"WP Cheshire","year":"1994","unstructured":"Cheshire WP, Abashian SW, Mann JD: Botulinum toxin in the treatment of myofascial pain syndrome. Pain 1994, 59:65\u201369.","journal-title":"Pain"},{"key":"65_CR22","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1097\/00007632-199808010-00009","volume":"23","author":"AH Wheeler","year":"1998","unstructured":"Wheeler AH, Goolkasian P, Gretz SS: A randomized, doubleblind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 1998, 23:1662\u20131666.","journal-title":"Spine"},{"key":"65_CR23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0304-3959(99)00264-X","volume":"85","author":"M Porta","year":"2000","unstructured":"Porta M: A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain 2000, 85:101\u2013105.","journal-title":"Pain"},{"key":"65_CR24","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/mds.870110425","volume":"11","author":"GW Paulson","year":"1996","unstructured":"Paulson GW, Gill W: Botulinum toxin is unsatisfactory therapy for fibromyalgia. Mov Disord 1996, 11:459.","journal-title":"Mov Disord"},{"key":"65_CR25","first-page":"1740","volume":"28","author":"RA Asherson","year":"2001","unstructured":"Asherson RA, Pascoe LP: The use of botulinum toxin-A in the treatment of patients with fibromyalgia. J Rheumatol 2001, 28:1740. A trial of fibromyalgia, but trigger points were injected. This trial involved open-label injections of botulinum toxin type A, often in multiple sessions. All 16 patients reportedly responded well, with benefit lasting for 16 weeks.","journal-title":"J Rheumatol"},{"key":"65_CR26","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/S0140-6736(05)62958-3","volume":"349","author":"HH Morre","year":"1997","unstructured":"Morre HH, Keizer SB, van Os JJ: Treatment of chronic tennis elbow with botulinum toxin. Lancet 1997, 349:1746.","journal-title":"Lancet"},{"key":"65_CR27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1212\/WNL.43.1_Part_1.183","volume":"43","author":"JK Tsui","year":"1993","unstructured":"Tsui JK, Bhatt M, Calne S, Calne DB: Botulinum toxin in the treatment of writer\u2019s cramp: a double-blind study. Neurology 1993, 43:183\u2013185.","journal-title":"Neurology"},{"key":"65_CR28","first-page":"R14","volume":"365","author":"M Bluthner","year":"2002","unstructured":"Bluthner M, Haugke C, Kalischewski P: The treatment of lateral epicondylitis elbow with botulinum toxin A: a first experience. Abstracts of the International Conference 2002: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. Arch Pharmacol 2002, 365:R14.","journal-title":"Arch Pharmacol"},{"key":"65_CR29","first-page":"R34","volume":"365","author":"R Placzek","year":"2002","unstructured":"Placzek R, Meiss L: Temporary chemical denervation with botulinum toxin A in epicondylitis radialis: a therapy trial in 14 patients. Abstracts of the International Conference 2002: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. Arch Pharmacol 2002, 365:R34.","journal-title":"Arch Pharmacol"},{"key":"65_CR30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0304-3959(99)00282-1","volume":"85","author":"LJ Kehl","year":"2000","unstructured":"Kehl LJ, Trempe TM, Hargreaves KM: A new animal model for assessing mechanisms and management of muscle hyperalgesia. Pain 2000, 85:333\u2013343.","journal-title":"Pain"},{"key":"65_CR31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00221-001-0941-4","volume":"142","author":"J Thunberg","year":"2002","unstructured":"Thunberg J, Ljubisavljevic M, Djupsjobacka M, Johansson H: Effects on the fusimotor-muscle spindle system induced by intramuscular injections of hypertonic saline. Exp Brain Res 2002, 142:319\u2013326.","journal-title":"Exp Brain Res"},{"key":"65_CR32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00002508-200103000-00002","volume":"17","author":"T Graven-Nielsen","year":"2001","unstructured":"Graven-Nielsen T, Mense S: The peripheral apparatus of muscle pain: evidence from animal and human studies. Clin J Pain 2001, 17:2\u201310. An excellent review of the pathophysiologic mechanisms of acute and chronic muscle pain.","journal-title":"Clin J Pain"},{"key":"65_CR33","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1177\/033310240102100706","volume":"21","author":"TS Jensen","year":"2001","unstructured":"Jensen TS: Recent advances in pain research: implications for chronic headache. Cephalalgia 2001, 21:765\u2013769.","journal-title":"Cephalalgia"},{"key":"65_CR34","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0304-3959(00)00287-6","volume":"87","author":"P Barlas","year":"2000","unstructured":"Barlas P, Walsh DM, Baxter GD, Allen JM: Delayed onset muscle soreness: effect of an ischemic block on mechanical allodynia in humans. Pain 2000, 87:221\u2013225.","journal-title":"Pain"},{"issue":"suppl 1","key":"65_CR35","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0885-3924(99)00120-7","volume":"19","author":"GJ Bennett","year":"2000","unstructured":"Bennett GJ: Update on the neurophysiology of pain transmission and modulation: focus on the NMDA-receptor. J Pain Symptom Manage 2000, 19(suppl 1):S2-S6.","journal-title":"J Pain Symptom Manage"},{"key":"65_CR36","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s004820100002","volume":"15","author":"S Mense","year":"2001","unstructured":"Mense S: Pathophysiology of low back pain and the transition to the chronic state: experimental data and new concepts. Schmerz 2001, 15:413\u2013417.","journal-title":"Schmerz"},{"key":"65_CR37","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0304-3959(00)00378-X","volume":"89","author":"L Zhang","year":"2001","unstructured":"Zhang L, Hoff AO, Wimalawansa SJ, et al.: Arthritic calcitonin\/ alpha calcitonin gene-related peptide knockout mice have reduced nociceptive hypersensitivity. Pain 2001, 89:265\u2013273.","journal-title":"Pain"},{"key":"65_CR38","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1046\/j.1468-2982.1999.019006602.x","volume":"19","author":"R Jensen","year":"1999","unstructured":"Jensen R: Pathophysiologic mechanisms of tension-type headache: a review of epidemiologic and experimental studies. Cephalalgia 1999, 19:602\u2013621.","journal-title":"Cephalalgia"},{"key":"65_CR39","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/(SICI)1097-4598(199811)21:11<1382::AID-MUS4>3.0.CO;2-5","volume":"21","author":"P Svensson","year":"1998","unstructured":"Svensson P, Graven-Nielsen T, Matre D, Arendt-Nielsen L: Experimental muscle pain does not cause long-lasting increases in resting electromyographic activity. Muscle Nerve 1998, 21:1382\u20131389.","journal-title":"Muscle Nerve"},{"key":"65_CR40","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1046\/j.1468-2982.2000.020004414.x","volume":"20","author":"M Cui","year":"2000","unstructured":"Cui M, Aoki R: Botulinum toxin A (BTX-a) reduces inflammatory pain in the rat formalin model. Cephalalgia 2000, 20:414\u20130.","journal-title":"Cephalalgia"},{"key":"65_CR41","first-page":"R39","volume":"365","author":"WJ Schulte-Matler","year":"2002","unstructured":"Schulte-Matler WJ, Blersch W, Przywara S, et al.: Botulinum toxin A and the cutaneous nociception in humans. Abstracts of the International Conference 2002: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. Arch Pharmacol 2002, 365:R39.","journal-title":"Arch Pharmacol"},{"key":"65_CR42","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1053\/gast.2001.24848","volume":"120","author":"JA McRoberts","year":"2001","unstructured":"McRoberts JA, Coutinho SV, Marvizon JC, et al.: Role of peripheral N-methyl-D-aspartate (NMDA) receptors in visceral nociception in rats. Gastroenterology 2001, 120:1737\u20131748.","journal-title":"Gastroenterology"},{"key":"65_CR43","first-page":"2906","volume":"27","author":"R Stefano De","year":"2000","unstructured":"De Stefano R, Selvi E, Villanova M, et al.: Image analysis quantification of substance P immunoreactivity in the trapezius muscle of patients with fibromyalgia and myofascial pain syndrome. J Rheumatol 2000, 27:2906\u20132910.","journal-title":"J Rheumatol"},{"key":"65_CR44","doi-asserted-by":"crossref","first-page":"R17","DOI":"10.1007\/s00210-001-0491-0","volume":"365","author":"M Cui","year":"2002","unstructured":"Cui M, Li Z, You S, Khanijou S, Aoki R: Mechanisms of the antinociceptive effect of subcutaneous Botox\": inhibition of peripheral and central nociceptive processing. Abstracts of the International Conference 2002: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. Arch Pharmacol 2002, 365:R17. Another important finding in the search for the mechanism of the analgesic action of botulinum toxin type A. Peripheral glutamate levels were reduced and central sensitization was prevented as a result.","journal-title":"Arch Pharmacol"},{"key":"65_CR45","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0021-5155(99)00197-5","volume":"44","author":"H Ishikawa","year":"2000","unstructured":"Ishikawa H, Mitsui Y, Yoshitomi T, et al.: Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol 2000, 44:106\u2013109.","journal-title":"Jpn J Ophthalmol"},{"key":"65_CR46","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1152\/ajpheart.2001.281.5.H2124","volume":"281","author":"JL Morris","year":"2001","unstructured":"Morris JL, Jobling P, Gibbins IL: Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol Heart Circ Physiol 2001, 281:2124\u20132132.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"65_CR47","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1067\/mmt.2000.109674","volume":"23","author":"GA Knutson","year":"2000","unstructured":"Knutson GA: The role of the gamma-motor system in increasing muscle tone and muscle pain syndromes: a review of the Johansson\/Sojka hypothesis. J Manipulative Physiol Ther 2000, 23:564\u2013572.","journal-title":"J Manipulative Physiol Ther"},{"key":"65_CR48","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3109\/00016489309135834","volume":"113","author":"GM Filippi","year":"1993","unstructured":"Filippi GM, Errico P, Santarelli R, et al.: Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 1993, 113:400\u2013404.","journal-title":"Acta Otolaryngol"},{"key":"65_CR49","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/(SICI)1097-4598(199604)19:4<488::AID-MUS9>3.0.CO;2-8","volume":"19","author":"RL Rosales","year":"1996","unstructured":"Rosales RL, Arimura K, Takenaga S, Osame M: Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 1996, 19:488\u2013496.","journal-title":"Muscle Nerve"},{"key":"65_CR50","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00498587","volume":"292","author":"H Wiegand","year":"1976","unstructured":"Wiegand H, Erdmann G, Wellhoner HH: 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol 1976, 292:161\u2013165.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"65_CR51","first-page":"337","volume":"8","author":"R Aoki","year":"1998","unstructured":"Aoki R: The development of Botox: its history and pharmacology. Pain Digest 1998, 8:337\u2013341.","journal-title":"Pain Digest"},{"key":"65_CR52","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0006-2952(00)00260-4","volume":"59","author":"J Purkiss","year":"2000","unstructured":"Purkiss J, Welch M, Doward S, Foster K: Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurone: involvement of two distinct mechanisms. Biochem Pharmacol 2000, 59:1403\u20131406.","journal-title":"Biochem Pharmacol"},{"key":"65_CR53","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0197-0186(99)00081-9","volume":"35","author":"MC Cuesta","year":"1999","unstructured":"Cuesta MC, Arcaya JL, Cano G, et al.: Opposite modulation of capsaicin-evoked substance P release by glutamate receptors. Neurochem Int 1999, 35:471\u2013478.","journal-title":"Neurochem Int"},{"key":"65_CR54","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0025-7125(05)70125-5","volume":"83","author":"MO Urban","year":"1999","unstructured":"Urban MO, Gebhart GF: Central mechanisms in pain. Med Clin North Am 1999, 83:585\u2013596.","journal-title":"Med Clin North Am"},{"key":"65_CR55","doi-asserted-by":"crossref","first-page":"21338","DOI":"10.1016\/S0021-9258(19)36614-1","volume":"267","author":"HT McMahon","year":"1992","unstructured":"McMahon HT, Foran P, Dolly JO, et al.: Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gammaaminobutyric acid, aspartate, and met-enkephalin release from synaptosomes: clues to the locus of action. J Biol Chem 1992, 267:21338\u201321343.","journal-title":"J Biol Chem"},{"key":"65_CR56","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0306-4522(96)00596-9","volume":"78","author":"HH Jung","year":"1997","unstructured":"Jung HH, Lauterburg T, Burgunder JM: Expression of neurotransmitter genes in rat spinal motoneurons after chemodenervation with botulinum toxin. Neuroscience 1997, 78:469\u2013479.","journal-title":"Neuroscience"},{"key":"65_CR57","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1006\/exnr.1999.7268","volume":"161","author":"AM Humm","year":"2000","unstructured":"Humm AM, Pabst C, Lauterburg T, Burgunder JM: Enkephalin and aFGF are differentially regulated in rat spinal motoneurons after chemodenervation with botulinum toxin. Exp Neurol 2000, 161:361\u2013372.","journal-title":"Exp Neurol"},{"key":"65_CR58","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1152\/jn.2001.85.1.280","volume":"85","author":"MM Heinricher","year":"2001","unstructured":"Heinricher MM, McGaraughty S, Tortorici V: Circuitry underlying antiopioid actions of cholecystokinin within the rostral ventromedial medulla. J Neurophysiol 2001, 85:280\u2013286.","journal-title":"J Neurophysiol"},{"key":"65_CR59","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1124\/jpet.300.2.647","volume":"300","author":"HE Wu","year":"2002","unstructured":"Wu HE, Hung KC, Mizoguchi H, et al.: Roles of endogenous opioid peptides in modulation of nocifensive response to formalin. J Pharmacol Exp Ther 2002, 300:647\u2013654.","journal-title":"J Pharmacol Exp Ther"},{"key":"65_CR60","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0306-4522(88)90018-8","volume":"25","author":"PK Mulderry","year":"1988","unstructured":"Mulderry PK, Ghatel MA, Spokes RA, et al.: Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience 1988, 25:195\u2013205.","journal-title":"Neuroscience"},{"key":"65_CR61","doi-asserted-by":"crossref","unstructured":"Duggan MJ, Quinn CP, Chaddock JA, et al.: Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J Biol Chem 2002, in press.","DOI":"10.1074\/jbc.M202902200"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-002-0065-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11916-002-0065-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-002-0065-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T14:18:37Z","timestamp":1628950717000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11916-002-0065-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,11]]}},"alternative-id":["65"],"URL":"https:\/\/doi.org\/10.1007\/s11916-002-0065-y","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,11]]}}}